|
|||||
|
|
Octreotide as first-line treatment for women with metastatic breast cancer |
|
| Authors: | James N. Ingle MD Carl G. Kardinal Vera J. Suman James E. Krook Alan K. Hatfield |
| Affiliation: | (1) Mayo Clinic and Mayo Foundation, 55905 Rochester, MN, USA;(2) Ochsner Community Clinical Oncology Program (CCOP), 70121 New Orleans, LA, USA;(3) Duluth CCOP, 55805 Duluth, MN, USA;(4) Carle Cancer Center CCOP, 61801 Urbana, IL, USA;(5) Mayo Clinic, 200 First Street SW, 55905 Rochester, MN, USA |
| Abstract: | Summary Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150  g subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days. |
| Keywords: | octreotide metastatic breast cancer |
| 本文献已被 SpringerLink 等数据库收录！ | |